SCHEMBL3210281

SCHEMBL3210281

O=S(=O)(c1ccccc1Cl)N1CCN(c2c(Cl)cncc2Cl)CC1

nearest known ligand 0.59

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
CHRM4 P08173 7/20 0.59
GBA1 P04062 2/20 0.51
CHRM2 P08172 1/20 0.48
CHRM5 P08912 1/20 0.48
CHRM1 P11229 1/20 0.48
CHRM3 P20309 1/20 0.48
ADRB2 P07550 1/20 0.45
CYP3A4 P08684 1/20 0.44
NAMPT P43490 1/20 0.44
KDM2B Q8NHM5 1/20 0.44
TSHR P16473 1/20 0.44
PIK3CA P42336 1/20 0.44
MTOR P42345 1/20 0.44
FAAH O00519 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5347507 0.95 CHRM4 (0.61) CHRM4GBA1CHRM2CHRM5CHRM1
SCHEMBL3223553 0.88 CHRM4 (0.61) CHRM4GBA1CHRM2CHRM5CHRM1
SCHEMBL14386523 0.83 CHRM4 (0.48) CHRM4CYP3A4NAMPTTSHR
SCHEMBL5331427 0.83 CHRM4 (0.48) CHRM4GBA1CYP3A4TSHR
SCHEMBL5350376 0.82 CHRM4 (0.63) CHRM4GBA1CHRM2CHRM5CHRM1
SCHEMBL10723724 0.82 CHRM4 (0.64) CHRM4GBA1CYP3A4TSHRFAAH
SCHEMBL5329287 0.81 MEN1 (0.60) CHRM4GBA1CYP3A4TSHR
SCHEMBL5351297 0.80 KDM4E (0.59) CHRM4GBA1CYP3A4KDM2BTSHR
SCHEMBL5349113 0.80 KMT2A (0.61) CHRM4GBA1TSHR
SCHEMBL5325641 0.80 PKM (0.51) CHRM4GBA1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100029648-A1 11-Beta HSD1 Inhibitors XIANG JASON SHAOYUN 2010-02-04 US disclosed
US-7632838-B2 11-beta HSD1 inhibitors WYETH (US) 2009-12-15 US disclosed
EP-1981848-A2 11-BETA HSD1 INHIBITORS Wyeth (US) 2008-10-22 EP disclosed
US-20070219198-A1 11-Beta HSD 1 inhibitors WYETH (US) 2007-09-20 US disclosed
WO-2007092435-A2 11-BETA HSD1 INHIBITORS WYETH (US) 2007-08-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029648-A1 11-Beta HSD1 Inhibitors HSD11B1, HSD3B1, HSD11B2 CHRM4 4870/4885GBA1 3525/4885CHRM2 4884/4885
US-20070219198-A1 11-Beta HSD 1 inhibitors HSD11B1, HSD11B2, HSD3B1 CHRM4 4818/4885GBA1 4014/4885CHRM2 4870/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.